論文

2019年9月

Fatty acid beta oxidation enzyme HADHA is a novel potential therapeutic target in malignant lymphoma.

Lab. Invest.
  • Kouhei Yamamoto
  • ,
  • Shinya Abe
  • ,
  • Ayaka Honda
  • ,
  • Jun Hashimoto
  • ,
  • Yuuki Aizawa
  • ,
  • Sachiko Ishibashi
  • ,
  • Taro Takemura
  • ,
  • Nobutaka Hanagata
  • ,
  • Masahide Yamamoto
  • ,
  • Osamu Miura
  • ,
  • Morito Kurata
  • ,
  • Masanobu Kitagawa

記述言語
英語
掲載種別
DOI
10.1038/s41374-019-0318-6

Cancer cells, including malignant lymphoma cells, alter their metabolism, termed "metabolic reprograming," on initiation of malignant transformation as well as upon accumulation of genetic abnormalities. Here, to identify a novel therapeutic target involved in the metabolic changes during malignant lymphoma, we performed global analyses combined with shotgun proteomics, in silico database analysis, and clinic-pathologic analysis of nonneoplastic lymphoid tissue and malignant lymphoma tissue and verified the molecular functions in vitro. In total, 2002 proteins were detected from both samples and proteins related to fatty acid beta-oxidation (FAO) were detected more frequently in malignant lymphoma tissue. Consequently, the most frequently detected protein, the mitochondrial trifunctional enzyme subunit-alpha (HADHA), was identified as a potential target. Immunohistochemical analyses revealed that HADHA tended to be overexpressed in a high-grade subtype of malignant lymphoma tissue. Clinicopathologic study revealed that HADHA overexpression was correlated with significantly worse overall survival (P = 0.013) and was an independent prognostic predictor in diffuse large B-cell lym

リンク情報
DOI
https://doi.org/10.1038/s41374-019-0318-6
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31527828